InVera Medical Achieves European CE Mark Approval for New Vein Infusion Device
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
14
Sab, Feb

Abbiamo 1869 visitatori e nessun utente online

InVera Medical Achieves European CE Mark Approval for New Vein Infusion Device

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ -- InVera Medical, an Irish medical technology company, has received European regulatory approval for a new minimally invasive device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose

veins. 

  

  

The approval, known as a CE Mark, allows the company's InVera Infusion Device to be marketed and used across the European Union. 

Unlike many existing technologies that burn the vein, the InVera device uses a non-thermal approach. The procedure is carried out in a doctor's office, requires only a single injection of local anaesthetic, and does not need specialised hospital equipment. This represents a major step forward in expanding non-thermal options for physicians in the management of Chronic Venous Disease. 

The device uses a thin catheter inserted into the vein under ultrasound guidance, a technique already familiar to many physicians, and is designed to enhance infusion of physician-specified agents more effectively inside the vein. 

Chronic Venous Disease affects around one in four adults and can progress from visible varicose veins to painful leg ulcers if left untreated. Despite estimated to affect over 120 million people across Europe and the US, only around 1% of those living with venous disease currently receive interventional treatment each year, underlining a significant gap in care that InVera aims to address. 

Stephen Cox, CEO and Co-Founder of InVera Medical, said: 

"Securing CE Mark is a major milestone for InVera Medical and a significant step towards making this technology available to patients across Europe. Our focus has been on developing a less-invasive, effective non-thermal approach that fits easily into existing clinical practice while improving the treatment experience for both physicians and patients." 

Founded in 2018, InVera Medical develops catheter-based technologies for vein disease. The company's mission is driven by a patient-first, scientifically grounded approach to innovation of safe and effective medical devices. The InVera Infusion device is CE Marked for use in the EU. It is not currently available in the US or any other international market. 

See more at www.inveramedical.com  

Logo: https://mma.prnewswire.com/media/2903220/InVera_Medical_Logo.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/invera-medical-achieves-european-ce-mark-approval-for-new-vein-infusion-device-302687559.html  

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

Author: RedWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.